Effect of intermittent fasting 16:8 and 14:10 compared with control-group on weight reduction and metabolic outcomes in obesity with type 2 diabetes patients: A randomized controlled trial.

Publisher: Asian Association for the Study of Diabetes and Blackwell Pub. Asia Country of Publication: Japan NLM ID: 101520702 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2040-1124 (Electronic) Linking ISSN: 20401116 NLM ISO Abbreviation: J Diabetes Investig Subsets: MEDLINE

Original Publication: Tokyo : Asian Association for the Study of Diabetes and Blackwell Pub. Asia

Diabetes Mellitus, Type 2*/metabolism ; Diabetes Mellitus, Type 2*/complications ; Weight Loss* ; Obesity*/metabolism ; Obesity*/complications ; Obesity*/diet therapy ; Fasting*; Humans ; Male ; Female ; Middle Aged ; Blood Glucose/analysis ; Blood Glucose/metabolism ; Adult ; Glycated Hemoglobin/analysis ; Treatment Outcome ; Follow-Up Studies ; Intermittent Fasting

Aims/introduction: To compare the percent weight change and metabolic outcomes among diabetic participants with obesity on intermittent fasting (IF) 16:8, IF 14:10, or normal controlled diets.
Materials and Methods: A randomized controlled trial was conducted to randomize participants into three groups. Each group followed IF 16:8, IF 14:10, according to the protocol 3 days/week for 3 months or a control group.
Results: A total of 99 participants completed the study. The percentage weight change from baseline was -4.02% (95% CI, -4.40 to -3.64) in IF 16:8, -3.15% (95% CI, -3.41 to -2.89) in IF 14:10, and -0.55% (95% CI, -1.05 to -0.05) in the control group. The percentage weight loss from baseline was significantly more in both IF groups (P < 0.001, both) when compared with the control group. Weight loss was significantly more in the IF 16:8 group than in that of the IF 14:10 group (P < 0.001). Metabolic outcomes (decrease in FBS and HbA1C, and improvement in lipid profiles) were significantly improved from baseline in both IF groups in comparison with the control group.
Conclusions: Either IF 16:8 or 14:10 had a benefit in the percentage weight change, glucose and lipid profiles in obese diabetic patients compared with the control group when consumed for 3 days a week for 3 months.
(© 2024 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.)

Curr Nutr Rep. 2021 Jun;10(2):146-154. (PMID: 33826120)
J Transl Med. 2016 Oct 13;14(1):290. (PMID: 27737674)
Cell Metab. 2020 Jan 7;31(1):92-104.e5. (PMID: 31813824)
J Clin Endocrinol Metab. 2021 Jun 16;106(7):1854-1866. (PMID: 33595666)
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33. (PMID: 33298413)
Nutrients. 2022 Jan 31;14(3):. (PMID: 35276989)
Heliyon. 2020 Sep 14;6(9):e04797. (PMID: 32964152)
J Am Acad Orthop Surg Glob Res Rev. 2018 Mar 23;2(3):e088. (PMID: 30211382)
Nutrients. 2019 Mar 28;11(4):. (PMID: 30925707)
Cell Metab. 2020 Sep 1;32(3):366-378.e3. (PMID: 32673591)
Cell Metab. 2012 Jun 6;15(6):848-60. (PMID: 22608008)
JAMA Intern Med. 2020 Nov 1;180(11):1491-1499. (PMID: 32986097)
BMJ Open Sport Exerc Med. 2022 Jan 7;8(1):e001206. (PMID: 35070352)
QJM. 2018 Jul 1;111(7):437-443. (PMID: 29025162)
Aging Clin Exp Res. 2011 Jun;23(3):209-16. (PMID: 21993168)
Nutr Metab (Lond). 2021 Oct 7;18(1):88. (PMID: 34620199)
Endocr Rev. 2022 Mar 9;43(2):405-436. (PMID: 34550357)
Front Nutr. 2023 May 09;10:1090792. (PMID: 37229479)
Int J Endocrinol. 2022 Mar 24;2022:6999907. (PMID: 35371260)
J Clin Endocrinol Metab. 2022 Nov 25;107(12):3428-3441. (PMID: 36190980)
J Biol Chem. 2007 Nov 23;282(47):34213-8. (PMID: 17884815)
Obesity (Silver Spring). 2019 May;27(5):724-732. (PMID: 31002478)
Nutr Diabetes. 2021 Jan 15;11(1):6. (PMID: 33446635)
Cell Metab. 2018 Jun 05;27(6):1212-1221.e3. (PMID: 29754952)
CMAJ. 2013 Jun 11;185(9):E363-4. (PMID: 23569168)
Nutr Res. 2016 Jun;36(6):603-11. (PMID: 27188906)
Public Health Nutr. 2002 Dec;5(6A):991-9. (PMID: 12633524)
Nutr Metab Cardiovasc Dis. 2018 Jul;28(7):698-706. (PMID: 29778565)
Br J Nutr. 2007 Mar;97(3):584-90. (PMID: 17313722)
Curr Atheroscler Rep. 2021 Mar 26;23(5):22. (PMID: 33772388)

2021 Endocrine Society of Thailand

Keywords: Intermittent fasting; Metabolic outcomes; Weight reduction

0 (Blood Glucose)
0 (Glycated Hemoglobin)
0 (hemoglobin A1c protein, human)

Date Created: 20240627 Date Completed: 20240830 Latest Revision: 20240901

20240901

PMC11363092

10.1111/jdi.14186

38932663